Harbour Capital Advisors LLC Purchases 1,611 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Harbour Capital Advisors LLC grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 33.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,452 shares of the company’s stock after acquiring an additional 1,611 shares during the quarter. Harbour Capital Advisors LLC’s holdings in TransMedics Group were worth $446,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of TMDX. Amalgamated Bank lifted its position in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the last quarter. National Bank of Canada FI grew its position in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares in the last quarter. Quarry LP increased its stake in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its position in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMDX. Oppenheimer reiterated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

Shares of TMDX stock opened at $64.05 on Tuesday. The company has a market capitalization of $2.15 billion, a P/E ratio of 68.14 and a beta of 2.12. The company’s 50-day simple moving average is $73.56 and its two-hundred day simple moving average is $120.20. TransMedics Group, Inc. has a one year low of $58.27 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period last year, the company earned ($0.12) EPS. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.